Overview of the recommendations adopted by the PRAC on signals discussed at the meeting of 31 August – 03 September 2020: medicinal products containing interferon alfa-2a, peginterferon alfa-2a – neuromyelitis optica spectrum disorders
01.10.2020
1691
Having reviewed the available evidence in EudraVigilance, the literature and data received from the registration certificate holders for the products IntronA, PegIntron, ViraferonPeg, Roferon-A, Pegasys,…
Read more